<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Cardiol</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Cardiology</journal-title></journal-title-group><issn pub-type="ppub">2380-6583</issn><issn pub-type="epub">2380-6591</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11024736</article-id><article-id pub-id-type="pmcid-ver">PMC11024736.1</article-id><article-id pub-id-type="pmcaid">11024736</article-id><article-id pub-id-type="pmcaiid">11024736</article-id><article-id pub-id-type="pmid">38630489</article-id><article-id pub-id-type="doi">10.1001/jamacardio.2024.0534</article-id><article-id pub-id-type="publisher-id">hoi240013</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-first"><subject>Online First</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk</article-title><subtitle>The OPT-BIRISK Randomized Clinical Trial</subtitle><alt-title alt-title-type="headline">Clopidogrel vs DAPT in Acute Coronary Syndromes and High Ischemic/Bleeding Risk</alt-title><alt-title alt-title-type="running-head">Clopidogrel vs DAPT in Acute Coronary Syndromes and High Ischemic/Bleeding Risk</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yi</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="J">Jing</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="B">Bin</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jing</surname><given-names initials="Q">Quanmin</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zeng</surname><given-names initials="Y">Yujie</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hou</surname><given-names initials="A">Aijie</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zhifang</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="A">Aijun</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jinliang</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yaojun</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="P">Ping</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="D">Daming</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="B">Bin</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fan</surname><given-names initials="J">Jiamao</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jun</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="L">Li</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff13" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Su</surname><given-names initials="G">Guohai</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff14" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="M">Ming</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff15" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="W">Weihong</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff16" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Qu</surname><given-names initials="P">Peng</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff17" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zeng</surname><given-names initials="H">Hesong</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="hoi240013aff18" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="L">Lu</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff19" ref-type="aff">
<sup>19</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Qiu</surname><given-names initials="M">Miaohan</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ru</surname><given-names initials="L">Leisheng</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff20" ref-type="aff">
<sup>20</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="S">Shaoliang</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff21" ref-type="aff">
<sup>21</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="Y">Yujie</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Qiao</surname><given-names initials="S">Shubin</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff22" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stone</surname><given-names initials="GW">Gregg W.</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff23" ref-type="aff">
<sup>23</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Angiolillo</surname><given-names initials="DJ">Dominick J.</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="hoi240013aff24" ref-type="aff">
<sup>24</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Han</surname><given-names initials="Y">Yaling</given-names></name><degrees>MD</degrees><xref rid="hoi240013aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><on-behalf-of>for the OPT-BIRISK Investigators</on-behalf-of></contrib-group><aff id="hoi240013aff1"><label>1</label>State Key Laboratory of Frigid Zone Cardiovascular Disease, General Hospital of Northern Theater Command, Shenyang, China</aff><aff id="hoi240013aff2"><label>2</label>Beijing Anzhen Hospital, Capital Medical University, Beijing, China</aff><aff id="hoi240013aff3"><label>3</label>The People&#8217;s Hospital of Liaoning Province, Shenyang, China</aff><aff id="hoi240013aff4"><label>4</label>Xinxiang Central Hospital, Xinxiang, China</aff><aff id="hoi240013aff5"><label>5</label>Benxi Central Hospital, Benxi, China</aff><aff id="hoi240013aff6"><label>6</label>Meihekou Central Hospital, Meiheko, China</aff><aff id="hoi240013aff7"><label>7</label>Xuzhou Third People&#8217;s Hospital, Xuzhou, China</aff><aff id="hoi240013aff8"><label>8</label>Beijing Tsinghua Changgung Hospital, Beijing, China</aff><aff id="hoi240013aff9"><label>9</label>Dandong Central Hospital, Dandong, China</aff><aff id="hoi240013aff10"><label>10</label>The Second Hospital of Jilin University, Changchun, China</aff><aff id="hoi240013aff11"><label>11</label>Linfen Central Hospital, Linfen, China</aff><aff id="hoi240013aff12"><label>12</label>Cangzhou Central Hospital, Cangzhou, China</aff><aff id="hoi240013aff13"><label>13</label>Guangzhou Red Cross Hospital, Guangzhou, China</aff><aff id="hoi240013aff14"><label>14</label>Central Hospital Affiliated to Shandong First Medical University, Ji&#8217;nan, China</aff><aff id="hoi240013aff15"><label>15</label>Yingkou Central Hospital, Yingkou, China</aff><aff id="hoi240013aff16"><label>16</label>The Third Xiangya Hospital of Central South University, Changsha, China</aff><aff id="hoi240013aff17"><label>17</label>The Second Hospital of Dalian Medical University, Dalian, China</aff><aff id="hoi240013aff18"><label>18</label>Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China</aff><aff id="hoi240013aff19"><label>19</label>The Second Affiliated Hospital of Shenyang Medical College, Shenyang, China</aff><aff id="hoi240013aff20"><label>20</label>Bethune International Peace Hospital, Shijiazhuang, China</aff><aff id="hoi240013aff21"><label>21</label>Nanjing First Hospital, Nanjing, China</aff><aff id="hoi240013aff22"><label>22</label>Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, China</aff><aff id="hoi240013aff23"><label>23</label>The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York</aff><aff id="hoi240013aff24"><label>24</label>University of Florida College of Medicine, Jacksonville</aff><author-notes><title>Article Information</title><p content-type="byline-footnote" specific-use="print"><bold>Group Information:</bold> The members of the OPT-BIRISK Investigators appear in Supplement 4.</p><p><bold>Accepted for Publication:</bold> February 2, 2024.</p><p content-type="published-online"><bold>Published Online:</bold> April 17, 2024. doi:<uri content-type="doi">10.1001/jamacardio.2024.0534</uri></p><corresp id="hoi240013cor1"><bold>Corresponding Author:</bold> Yaling Han, MD, State Key Laboratory of Frigid Zone Cardiovascular Disease, General Hospital of Northern Theater Command, 83 Wenhua Road, Shenyang 110016, China (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hanyaling@263.net">hanyaling@263.net</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Han had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Y. Li and J. Li contributed equally to this work.</p><p><italic toggle="yes">Concept and design:</italic> Y. Li, Z. Wang, B. Liu, Jun Zhang, Li Li, Qu, Qiu, Chen, Zhou, Han.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Y. Li, J. Li, B. Wang, Jing, Y. Zeng, Hou, Z. Wang, A. Liu, Jinliang Zhang, Y. Zhang, P. Zhang, D. Jiang, B. Liu, Fan, Jun Zhang, Su, Yang, W. Jiang, Qu, H. Zeng, Lu Li, Qiu, Ru, Chen, Qiao, Stone, Angiolillo, Han.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Y. Li, J. Li, Jing, Hou, Z. Wang, Jinliang Zhang, B. Liu, Fan, Jun Zhang, Li Li, Qu, Chen, Stone, Han.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> B. Wang, Y. Zeng, Z. Wang, A. Liu, Y. Zhang, P. Zhang, D. Jiang, B. Liu, Jun Zhang, Su, Yang, W. Jiang, Qu, H. Zeng, Lu Li, Qiu, Ru, Chen, Zhou, Qiao, Stone, Angiolillo, Han.</p><p><italic toggle="yes">Statistical analysis:</italic> Y. Li, J. Li, Jing, Hou, Z. Wang, A. Liu, Jinliang Zhang, Y. Zhang, B. Liu, Fan, Jun Zhang, Qiu, Chen, Zhou, Han.</p><p><italic toggle="yes">Obtained funding:</italic> Zhou, Han.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> B. Wang, Z. Wang, P. Zhang, Jun Zhang, Su, Qu, H. Zeng, Ru, Chen, Zhou, Han.</p><p><italic toggle="yes">Supervision:</italic> B. Liu, Jun Zhang, Qu, Ru, Chen, Zhou, Stone, Angiolillo, Han.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Stone reported receiving speaker fees from Medtronic, Pulnovo, Infraredx, Abiomed, Amgen, and Boehringer Ingelheim; consultant fees from Abbott, Daiichi Sankyo, Ablative Solutions, CorFlow, Cardiomech, Gore, Robocath, Miracor, Vectorious, Abiomed, Valfix, Apollo Therapeutics, TherOx, HeartFlow, Neovasc, Ancora, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical, Millennia Biopharma, Oxitope, Cardiac Success, and HighLife; research funding from Ancora, Cagent, Applied Therapeutics, and Biostar; equity or options from SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, and Xenter; and research grants from Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo, and V-wave outside the submitted work. Dr Angiolillo reported receiving consulting fees from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, CSL Behring, Daiichi Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, Novartis, PhaseBio, PLx Pharma, Pfizer, Sanofi, and Vectura and research grants from Amgen, AstraZeneca, Bayer, Biosensors, Celo-Nova, CSL Behring, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, and the Scott R. MacKenzie Foundation. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This trial was funded by grants 2016YFC1301300, 2016YFC1301303, and 2022YFC2503500 from the <funding-source rid="sp1">National Key Research and Development Project</funding-source> and a research grant from Sanofi-Aventis Co. Ltd (Paris, France).</p><p><bold>Role of the Funder/Sponsor:</bold> The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p><bold>Group Information:</bold> The members of the OPT-BIRISK Investigators are listed in <xref rid="note-HOI240013-1-s" ref-type="supplementary-material">Supplement 4</xref>.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-HOI240013-1-s" ref-type="supplementary-material">Supplement 5</xref>.</p><p><bold>Additional Contributions:</bold> We thank the investigator members of the OPT-BIRISK study group and Drs Xiaozeng Wang, MD (General Hospital of Northern Theater Command), Geng Wang, MD (General Hospital of Northern Theater Command), Kai Xu, MD (General Hospital of Northern Theater Command), Haiwei Liu, MD (General Hospital of Northern Theater Command), Yingyan Ma, MD (General Hospital of Northern Theater Command), Zhenyang Liang, MD (General Hospital of Northern Theater Command), Shaoyi Guan, MD (General Hospital of Northern Theater Command), Nan Ma, PhD (General Hospital of Northern Theater Command), Yuxin Dong, MBBS (CCRF [Beijing] Co Ltd), Peng Fan, MD (General Hospital of Northern Theater Command), Xinxin Yuan, MBBS (CCRF [Beijing] Co Ltd), Yu Zhao, MD (General Hospital of Northern Theater Command), Shanbao Chen, MD (General Hospital of Northern Theater Command), and Wenjing Dou, MD (General Hospital of Northern Theater Command), for coordination of the study.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2024-04-17T10:00"><day>17</day><month>4</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2024</year></pub-date><volume>9</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">460209</issue-id><fpage>523</fpage><lpage>531</lpage><history><date date-type="received"><day>4</day><month>7</month><year>2023</year></date><date date-type="accepted"><day>2</day><month>2</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>17</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-17 00:25:47.990"><day>17</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2024 American Medical Association. All Rights Reserved.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamacardiol-e240534.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamacardiol-e240534.pdf">jamacardiol-e240534.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/cardiology/fullarticle/10.1001/jamacardio.2024.0534"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" journal-id="JAMA Cardiol" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="38630487"><article-title>Clopidogrel Monotherapy for Double-Risk Acute Coronary Syndrome.</article-title><date><day>17</day><month>4</month><year>2024</year></date><source>JAMA Cardiol</source><pub-id pub-id-type="doi">10.1001/jamacardio.2024.0547</pub-id><pub-id pub-id-type="pmid">38630487</pub-id></related-article><abstract abstract-type="teaser" specific-use="electronic"><p>This randomized clinical trial evaluates clopidogrel monotherapy vs dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions who are at high bleeding and ischemic risk.</p></abstract><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-hoi240013-1"><title>Question</title><p>What is the optimal antiplatelet regimen in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary interventions (PCIs) who are at both high bleeding and ischemic risks (birisk)?</p></sec><sec id="ab-hoi240013-2"><title>Findings</title><p>In this double-blind, randomized clinical trial including 7758 PCI-treated birisk patients with ACS who completed 9 to 12 months of dual antiplatelet therapy (DAPT) after PCI, clopidogrel monotherapy for an additional 9 months resulted in a 25% reduction in the risk of Bleeding Academic Research Consortium types 2, 3, or 5 bleeding compared with clopidogrel plus aspirin.</p></sec><sec id="ab-hoi240013-3"><title>Meaning</title><p>Among birisk patients with ACS who completed 9 to 12 months of DAPT after PCI, subsequent treatment with clopidogrel was superior to continuing DAPT with aspirin and clopidogrel in reducing clinically relevant bleeding.</p></sec></abstract><abstract><sec id="ab-hoi240013-4"><title>Importance</title><p>Purinergic receptor P2Y12 (P2Y12) inhibitor monotherapy after a certain period of dual antiplatelet therapy (DAPT) may be an attractive option of maintenance antiplatelet treatment for patients undergoing percutaneous coronary intervention (PCI) who are at both high bleeding and ischemic risk (birisk).</p></sec><sec id="ab-hoi240013-5"><title>Objective</title><p>To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing DAPT with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in birisk patients with acute coronary syndromes (ACS).</p></sec><sec id="ab-hoi240013-6"><title>Design, Setting, and Participants</title><p>This was a multicenter, double-blind, placebo-controlled, randomized clinical trial including birisk patients with ACS who had completed 9 to 12 months of DAPT after drug-eluting stent implantation and were free from adverse events for at least 6 months at 101 China centers between February 2018 and December 2020. Study data were analyzed from April 2023 to May 2023.</p></sec><sec id="ab-hoi240013-7"><title>Interventions</title><p>Patients were randomized either to clopidogrel plus placebo or clopidogrel plus aspirin for an additional 9 months.</p></sec><sec id="ab-hoi240013-8"><title>Main Outcomes and Measures</title><p>The primary end point was Bleeding Academic Research Consortium (BARC) types 2, 3, or 5 bleeding 9 months after randomization. The key secondary end point was major adverse cardiac and cerebral events (MACCE; the composite of all-cause death, myocardial infarction, stroke or clinically driven revascularization). The primary end point was tested for superiority, and the MACCE end point was tested for sequential noninferiority and superiority.</p></sec><sec id="ab-hoi240013-9"><title>Results</title><p>A total of 7758 patients (mean [SD] age, 64.8 [9.0] years; 4575 male [59.0%]) were included in this study. The primary end point of BARC types 2, 3, or 5 bleeding occurred in 95 of 3873 patients (2.5%) assigned to clopidogrel plus placebo and 127 of 3885 patients (3.3%) assigned to clopidogrel plus aspirin (hazard ratio [HR], 0.75; 95% CI, 0.57-0.97; difference, &#8722;0.8%; 95% CI, &#8722;1.6% to &#8722;0.1%; <italic toggle="yes">P</italic>&#8201;=&#8201;.03). The incidence of MACCE was 2.6% (101 of 3873 patients) in the clopidogrel plus placebo group and 3.5% (136 of 3885 patients) in the clopidogrel plus aspirin group (HR, 0.74; 95% CI, 0.57-0.96; difference, &#8722;0.9%; 95% CI, &#8722;1.7% to &#8722;0.1%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001 for noninferiority; <italic toggle="yes">P</italic>&#8201;=&#8201;.02 for superiority).</p></sec><sec id="ab-hoi240013-10"><title>Conclusions and Relevance</title><p>Among birisk patients with ACS who completed 9 to 12 months of DAPT after drug-eluting stent implantation and were free from adverse events for at least 6 months before randomization, an extended 9-month clopidogrel monotherapy regimen was superior to continuing DAPT with clopidogrel in reducing clinically relevant bleeding without increasing ischemic events.</p></sec><sec id="ab-hoi240013-11"><title>Trial Registration</title><p>ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://classic.clinicaltrials.gov/ct2/show/NCT03431142" ext-link-type="uri">NCT03431142</ext-link></p></sec></abstract><funding-group><award-group><funding-source id="sp1">National Key Research and Development Project</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>